Psychiatric Times articleshttps://www.psychiatrictimes.com/newsPsychiatric Times articles© 2026 MJH Life Sciences™ and Psychiatric Times. All rights reserved.Fri, 08 May 2026 03:34:00 +00005en-us14447https://www.psychiatrictimes.com/newshttps://www.psychiatrictimes.com/logo.webphttps://www.psychiatrictimes.com/view/antidepressant-treatment-personalized-by-preference-not-pharmacogenomicshttps://www.psychiatrictimes.com/view/antidepressant-treatment-personalized-by-preference-not-pharmacogenomics<![CDATA[Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.]]>Thu, 07 May 2026 15:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/pharmacogenomics-in-psychiatry-starting-with-the-molecular-basicshttps://www.psychiatrictimes.com/view/pharmacogenomics-in-psychiatry-starting-with-the-molecular-basics<![CDATA[Learn how genetics shape psych med response and dosing.]]>Thu, 07 May 2026 14:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/psychiatrys-medication-pipeline-in-motionhttps://www.psychiatrictimes.com/view/psychiatrys-medication-pipeline-in-motion<![CDATA[New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.]]>Thu, 07 May 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/fda-clears-clinical-trial-of-nrx-101-in-combination-with-robotic-enabled-tms-in-patients-with-depression-and-suicidalityhttps://www.psychiatrictimes.com/view/fda-clears-clinical-trial-of-nrx-101-in-combination-with-robotic-enabled-tms-in-patients-with-depression-and-suicidality<![CDATA[FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.]]>Thu, 07 May 2026 13:20:09 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/what-clinicians-need-to-know-about-the-federal-push-for-deprescribing-a-conversation-with-joseph-f-goldberg-mdhttps://www.psychiatrictimes.com/view/what-clinicians-need-to-know-about-the-federal-push-for-deprescribing-a-conversation-with-joseph-f-goldberg-md<![CDATA[HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.]]>Wed, 06 May 2026 18:21:34 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/psychiatric-deprescribing-the-need-for-nuanced-approacheshttps://www.psychiatrictimes.com/view/psychiatric-deprescribing-the-need-for-nuanced-approaches<![CDATA[HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.]]>Wed, 06 May 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/personalized-medicine-in-schizophrenia-moving-beyond-diagnosis-to-patient-centered-carehttps://www.psychiatrictimes.com/view/personalized-medicine-in-schizophrenia-moving-beyond-diagnosis-to-patient-centered-care<![CDATA[Tracy Hicks, DNP, FNP/PMHNP-BC, outlines how personalized, team-based care and shared decision-making can improve schizophrenia outcomes in real-world practice.]]>Wed, 06 May 2026 16:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/using-neuromelanin-sensitive-mri-to-examine-catecholaminergic-disorders-over-timehttps://www.psychiatrictimes.com/view/using-neuromelanin-sensitive-mri-to-examine-catecholaminergic-disorders-over-time<![CDATA[Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.]]>Wed, 06 May 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/anchoring-on-risperidone-a-case-based-discussion-of-managing-hyperprolactinemia-with-dual-antipsychoticshttps://www.psychiatrictimes.com/view/anchoring-on-risperidone-a-case-based-discussion-of-managing-hyperprolactinemia-with-dual-antipsychotics<![CDATA[Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.]]>Wed, 06 May 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/cannabis-and-psychosis-risk-how-legalization-could-impact-clinical-practicehttps://www.psychiatrictimes.com/view/cannabis-and-psychosis-risk-how-legalization-could-impact-clinical-practice<![CDATA[New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.]]>Tue, 05 May 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/hhs-launches-action-plan-to-promote-appropriate-psychiatric-prescribinghttps://www.psychiatrictimes.com/view/hhs-launches-action-plan-to-promote-appropriate-psychiatric-prescribing<![CDATA[HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.]]>Tue, 05 May 2026 13:49:43 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-human-brain-vs-the-chatbot-brainhttps://www.psychiatrictimes.com/view/the-human-brain-vs-the-chatbot-brain<![CDATA[Explore how chatbot brains diverge and compete with human brains. ]]>Tue, 05 May 2026 13:45:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/lumateperone-ranks-highest-among-adjunctive-mdd-therapies-in-first-network-meta-analysishttps://www.psychiatrictimes.com/view/lumateperone-ranks-highest-among-adjunctive-mdd-therapies-in-first-network-meta-analysis<![CDATA[New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.]]>Mon, 04 May 2026 17:06:32 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/agitation-in-alzheimer-disease-dementia-practical-insights-for-clinicianshttps://www.psychiatrictimes.com/view/agitation-in-alzheimer-disease-dementia-practical-insights-for-clinicians<![CDATA[Learn how to better assess and manage behavioral and psychological symptoms of Alzheimer disease dementia. ]]>Mon, 04 May 2026 16:09:29 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/network-homeostasis-in-schizophrenia-why-finding-reduction-of-a-csf-molecule-may-advance-treatmenthttps://www.psychiatrictimes.com/view/network-homeostasis-in-schizophrenia-why-finding-reduction-of-a-csf-molecule-may-advance-treatment<![CDATA[Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.]]>Mon, 04 May 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/morning-rounds-news-from-april-27-may-1https://www.psychiatrictimes.com/view/morning-rounds-news-from-april-27-may-1<![CDATA[Round on the latest news in psychiatry from the last week.]]>Mon, 04 May 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/new-span-survey-highlights-persistent-gaps-in-schizophrenia-care-despite-advancing-treatment-landscapehttps://www.psychiatrictimes.com/view/new-span-survey-highlights-persistent-gaps-in-schizophrenia-care-despite-advancing-treatment-landscape<![CDATA[The SPAN survey underscores gaps in schizophrenia care access as new treatments emerge, citing coverage and continuity challenges.]]>Fri, 01 May 2026 15:23:58 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-the-intersection-of-psychotherapy-and-psychopharmacology-for-mood-disorders-optimizing-patient-outcomes-with-holly-a-swartz-mdhttps://www.psychiatrictimes.com/view/podcast-the-intersection-of-psychotherapy-and-psychopharmacology-for-mood-disorders-optimizing-patient-outcomes-with-holly-a-swartz-md<![CDATA[Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast. ]]>Fri, 01 May 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/switching-to-cobenfy-data-insights-at-sirs-from-harald-hampel-md-phd-mschttps://www.psychiatrictimes.com/view/switching-to-cobenfy-data-insights-at-sirs-from-harald-hampel-md-phd-msc<![CDATA[New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.]]>Fri, 01 May 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/presenting-our-may-2026-theme-psychedelicshttps://www.psychiatrictimes.com/view/presenting-our-may-2026-theme-psychedelics<![CDATA[In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.]]>Fri, 01 May 2026 14:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/building-community-in-psychiatric-practice-reflections-from-a-psych-np-and-educatorhttps://www.psychiatrictimes.com/view/building-community-in-psychiatric-practice-reflections-from-a-psych-np-and-educator<![CDATA[A psychiatrist and psychiatric nurse practitioner discuss collaboration and patient support.]]>Fri, 01 May 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/april-2026-in-review-updates-on-the-psychiatric-treatment-pipelinehttps://www.psychiatrictimes.com/view/april-2026-in-review-updates-on-the-psychiatric-treatment-pipeline<![CDATA[Check out the pipeline updates from April!]]>Thu, 30 Apr 2026 20:02:56 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-approval-of-auvelity-the-second-treatment-for-alzheimer-disease-agitationhttps://www.psychiatrictimes.com/view/the-approval-of-auvelity-the-second-treatment-for-alzheimer-disease-agitation<![CDATA[Auvelity is now approved for the treatment of Alzheimer disease agitation. Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, weighs in. ]]>Thu, 30 Apr 2026 18:56:57 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/fda-approves-auvelity-for-treatment-of-agitation-in-alzheimer-diseasehttps://www.psychiatrictimes.com/view/fda-approves-auvelity-for-treatment-of-agitation-in-alzheimer-disease<![CDATA[The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.]]>Thu, 30 Apr 2026 18:32:33 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/axs-05-approval-for-agitation-in-alzheimer-disease-notes-from-john-j-miller-mdhttps://www.psychiatrictimes.com/view/axs-05-approval-for-agitation-in-alzheimer-disease-notes-from-john-j-miller-md<![CDATA[FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.]]>Thu, 30 Apr 2026 18:26:34 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-saint-trial-expanding-rtms-for-postpartum-depressionhttps://www.psychiatrictimes.com/view/the-saint-trial-expanding-rtms-for-postpartum-depression<![CDATA[A multicenter study tests SAINT TMS for postpartum depression.]]>Thu, 30 Apr 2026 17:15:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/rational-off-label-prescribing-a-review-with-joseph-f-goldberg-md-and-henry-nasrallah-md-part-2https://www.psychiatrictimes.com/view/rational-off-label-prescribing-a-review-with-joseph-f-goldberg-md-and-henry-nasrallah-md-part-2<![CDATA[Clinicians explore neuroscience-guided off-label prescribing.]]>Thu, 30 Apr 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/psychiatry-does-not-need-a-softer-dsm-it-needs-a-smarter-onehttps://www.psychiatrictimes.com/view/psychiatry-does-not-need-a-softer-dsm-it-needs-a-smarter-one<![CDATA[DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.]]>Thu, 30 Apr 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/investigating-the-effect-of-psilocybin-in-treatment-resistant-depressionhttps://www.psychiatrictimes.com/view/investigating-the-effect-of-psilocybin-in-treatment-resistant-depression<![CDATA[The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.]]>Wed, 29 Apr 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/patent-issued-for-novel-genetic-biomarker-dgm4-identified-through-liafensine-program-for-treatment-resistant-depressionhttps://www.psychiatrictimes.com/view/patent-issued-for-novel-genetic-biomarker-dgm4-identified-through-liafensine-program-for-treatment-resistant-depression<![CDATA[New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.]]>Wed, 29 Apr 2026 14:05:53 GMTPsychiatric TimesusPsychiatric Times Articles